Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 18/20 | 0.48 |
| ▸ | EDNRB | P24530 | 11/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3801811 | 0.93 | EDNRA (0.46) | EDNRAEDNRB | |
| SCHEMBL4632365 | 0.92 | EDNRA (0.55) | EDNRAEDNRB | |
| Hydrochloric Acid SCHEMBL4631426 | 0.91 | EDNRA (0.54) | EDNRAEDNRB | |
| SCHEMBL5209011 | 0.88 | EDNRA (0.50) | EDNRAEDNRB | |
| SCHEMBL12934042 | 0.85 | EDNRA (0.39) | EDNRAEDNRB | |
| SCHEMBL4631395 | 0.84 | ALDH1A1 (0.39) | EDNRAEDNRBALDH1A1 | |
| SCHEMBL7081510 | 0.83 | EDNRA (0.51) | EDNRAEDNRB | |
| SCHEMBL3797336 | 0.83 | EDNRA (0.54) | EDNRAEDNRB | |
| SCHEMBL6955969 | 0.82 | EDNRA (0.56) | EDNRAEDNRB | |
| SCHEMBL3631928 | 0.82 | EDNRA (0.59) | EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1498418-B1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-0980369-B1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1498418-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1498419-A1 | Process for preparing alkali metal salts of hydrophobic sulfonamides | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6683103-B2 | SULFONAMIDES CONTAINING OXAZOLE AND SUBSTITUTED THIOPHENE RINGS, USEFUL FOR TREATING HYPERTENSION, CARDIOVASCULAR DISEASE, ASTHMA, PULMONARY HYPERTENSION, INFLAMMATORY DISEASES, VISION DEFECTS, MENSTRUAL DISORDERS, RENAL FAILURE | TEXAS BIOTECHNOLOGY CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6432994-B1 | CARDIOVASCULAR DISORDERS, GLAUCOMA; ANTIINFLAMMATORY, WOUND HEALING, HYPOTENSIVE, ANTIASTHMATIC, AND ANTIANAPHYLACTIC AGENTS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
| EP-0980369-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998049162-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | EDNRA, ECE1, EDNRB | EDNRA 1/4885EDNRB 3/4885ALDH1A1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.